This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Management of NSTE ACS Cath Lab Patients A Contemporary European Perspective
* NSTE-ACS
* GRACE Score
* TIMI Risk Score
* ISAR-COOL
* ISAR-COOL Major Results at 30 Days
* Caveats
* Caveats
* Importance of Physical Exam & Echocardiography
* 5.2% of NSTE-ACS Patients Significant Antecedent Valve Disease
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
n/a
n/a
|
|